^
Association details:
| Biomarker: | TP53 mutation |
|---|---|
| Cancer: | Multiple Myeloma |
| Drug: | Melflufen (melphalan flufenamide) (Alkylating agent) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Abstract 1843: Melflufen efficacy in multiple myeloma with TP53 aberrations
Published date:
05/15/2020
Excerpt:
It demonstrates better ex vivo efficacy in MM patient derived plasma cells harboring del17p or TP53 mutations.
DOI:
10.1158/1538-7445.AM2020-1843
Source:
Title:
EXPRESSION SIGNIFICANCE OF CRL4-CRBN PROTEINS COMPLEX IN MULTIPLE MYELOMA PATIENTS TREATED WITH IMMUNOMODULATORY DRUGS.
Published date:
05/14/2020
Excerpt:
Melflufen is able to trigger myeloma cell death regardless of p53 status, and thus overcome p53-deficiency-mediated melphalan resistance. It demonstrates better ex vivo efficacy in MM patient derived plasma cells harboring del17p or TP53 mutations. Melflufen response rates in the del17p patient subpopulation are comparable to the general patient population comprising RRMM exposed to IMiD- and proteasome inhibitors and resistant to daratumumab- and/or pomalidomide-based salvage therapies. Collectively, these data suggest that melflufen might provide a valuable therapeutic option for this difficult-to-treat patient group.
